roche_dark_0

FDA puts multiple myeloma trial on hold after patient deaths

pharmafile | March 20, 2019 | News story | Research and Development |  AbbVie, FDA, Roche, clinical trials, multiple myeloma 

The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of patient deaths in a late stage study.

AbbVie who are developing the drug with Roche said the hold should not affect any of the approved indications such as in chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML).

The FDA made the decision after seeing data from the Phase 3 BELLINI trial in patients with relapsed and refractory multiple myeloma.

Advertisement

The data showed a higher proportion of deaths in the Venclexta/Venclyxto arm compared to the control arm.

While 41 of 194 patients in the Venclexta/Venclyxto died, just 11 of 97 subjects in the placebo arm suffered a similar fate.

There were 13 treatment emergent deaths in the Venclexta/Venclyxto arm compared to just one in the placebo arm.

AbbVie president Michael Severino stated “we will continue working with the FDA and worldwide regulatory agencies to determine appropriate next steps for the multiple myeloma programme.”

The company “remains confident in the benefit/risk profile of [the drug] in [its] approved indications,” AbbVie said.

Louis Goss

Related Content

Most advanced breast cancer patients treated in community settings, Phesi study finds

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …

Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison

Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose …

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

The Gateway to Local Adoption Series

Latest content